NapaJen
NapaJen Pharma is a biopharmaceutical research and development company focused on creating nucleic acid medicines using proprietary technology. They aim to deliver nucleic acid drugs to immune cells, significantly shorten drug development periods, and contribute to new drug creation through collaborations with other pharmaceutical companies.
Industries
Nr. of Employees
small (1-50)
Patents
Products
NJA-730 (RNAi therapeutic candidate)
An RNAi-based therapeutic candidate developed using a cell-specific oligonucleotide delivery platform that progressed to a Phase I clinical trial in Australia.
Cell-specific oligonucleotide drug delivery platform
A technology platform for loading and delivering different oligonucleotide drugs to specified immune cell types to achieve precision immunomodulation.
NJA-730 (RNAi therapeutic candidate)
An RNAi-based therapeutic candidate developed using a cell-specific oligonucleotide delivery platform that progressed to a Phase I clinical trial in Australia.
Cell-specific oligonucleotide drug delivery platform
A technology platform for loading and delivering different oligonucleotide drugs to specified immune cell types to achieve precision immunomodulation.
Services
Collaborative services from early target selection through application of cell-targeted delivery technology to partner candidates; includes technology-sharing and joint research projects.
Provision of preclinical evaluation and demonstration of targeted immunomodulatory effects using cell-targeted oligonucleotide delivery platforms.
Collaborative services from early target selection through application of cell-targeted delivery technology to partner candidates; includes technology-sharing and joint research projects.
Provision of preclinical evaluation and demonstration of targeted immunomodulatory effects using cell-targeted oligonucleotide delivery platforms.
Expertise Areas
- Nucleic acid (oligonucleotide/RNAi) therapeutic development
- Cell-targeted drug delivery
- Immunotherapy and immune-cell modulation
- Preclinical to early clinical translation
Key Technologies
- Oligonucleotide therapeutics (RNAi)
- Cell-specific drug delivery platforms
- Dendritic cell targeting/modulation
- Dectin-1 receptor-mediated delivery
News & Updates
Presentation at Link-J.
Company featured in the Journal of the Japanese Nucleic Acid Medicine Society.
Completed Series C financing with a total of US$12.4 million.
Established an Australian subsidiary.
Company featured in Bio Venture Directory 2019-2020 by Nikkei BP.
Chief Scientific Officer Sakurai received the Nagai Award from the Japanese DDS Society.
Presentation at Link-J.
Company featured in the Journal of the Japanese Nucleic Acid Medicine Society.
Completed Series C financing with a total of US$12.4 million.
Established an Australian subsidiary.
Company featured in Bio Venture Directory 2019-2020 by Nikkei BP.
Chief Scientific Officer Sakurai received the Nagai Award from the Japanese DDS Society.